Editing Essential thrombocythemia (section)

===Indications===
Not all those affected will require treatment at presentation.<ref name="man1">{{cite journal |last=Cervantes |first=F |s2cid=18862829 |title= Management of Essential Thrombocythemia|journal=Hematology |date=2011 |volume=2011 |pages=215–21 |doi=10.1182/asheducation-2011.1.215 |pmid=22160037 |doi-access=free }}</ref><ref name="man2">{{cite journal |last=Birgegård |first=G |s2cid=11357000 |title=Pharmacological management of essential thrombocythemia. |journal=Expert Opinion on Pharmacotherapy |date=July 2013 |volume=14 |issue=10 |pages=1295–306 |doi=10.1517/14656566.2013.797408 |pmid=23668666}}</ref><ref name="man3">{{cite journal |last1=Tefferi |first1=A |last2=Barbui |first2=T |title=Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. |journal=Leukemia |date=August 2013 |volume=27 |issue=8 |pages=1617–20 |doi=10.1038/leu.2013.99 |pmid=23558521 |pmc=3740400}}</ref> Patients are usually designated as having a low or high risk of bleeding or developing blood clots based on their age, medical history, blood counts and their lifestyles. Low risk individuals are usually treated with [[aspirin]], whereas those at high risk are treated with [[hydroxycarbamide]], [[interferon-α]] or [[anagrelide]].<ref name="path" /><ref name="man1" /><ref name="man2" /><ref name="man3" /> Currently unapproved but in late-stage clinical trials (NCT04254978) are agents that lower platelets such as [[bomedemstat]].